Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan
ACE and DCE were not cost-effective compared with CE as first-line therapy for ED-SCLC in Japan. Both these therapies exhibited high ICERs.
Authors
- Miho Tsukada
- Munenobu Kashiwa (ORCID: https://orcid.org/0000-0001-5178-611X)
- Ryo Matsushita (ORCID: https://orcid.org/0000-0003-4333-7167)
Institutions
- Kanazawa University (JP)
- Ritsumeikan University (JP)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2024-09-21
- DOI
- https://doi.org/10.1007/s40261-024-01383-x
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Kanazawa University
- Japan Society for the Promotion of Science